Related Experiment Video
Updated: May 2, 2026
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
Antitumor Effect of Oleoyl-siRNA against Pancreatic Cancer Using a Portal Vein Infusion Liver-Metastatic Mouse Model
Takanori Kubo1, Kazuyoshi Yanagihara1,2, Yoshio Nishimura3
1Laboratory of Molecular Cell Biology, Department of Life Science, Faculty of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan.
Abstract:
In this study, we developed an oleoyl-siRNA conjugate in which oleic acid was conjugated at the 5'-end of the sense strand of the siRNA. Furthermore, we examined the effects of RNAi in a mouse model of pancreatic cancer with liver metastasis. The mouse model of pancreatic cancer with liver metastasis was developed by implanting Sui67Luc human pancreatic cancer cells into the portal veins of mice. Sui67Luc cells have high expression of tumor-related genes such as β-catenin, vascular endothelial growth factor, and programmed cell death ligand-1. All genes were knocked down using siRNA, among which siRNA targeting β-catenin exhibited the most suitable RNAi effect. Therefore, we investigated the in vitro RNAi effect of oleoyl-siRNA (Ole-siRNA) targeting the β-catenin gene in Sui67Luc cells and found that it was stronger than that of unmodified siRNA. For in vivo experiments, we investigated the biodistribution, antitumor effect, and change in life expectancy of mice upon systemic administration of Ole-siRNA complexed with Invivofectamine 3.0 (IVF). In terms of biodistribution, the Ole-siRNA/IVF complex likely accumulates in the liver of mice. The antitumor effect of Ole-siRNA in a portal vein infusion liver-metastatic Sui67Luc tumor mouse model was evaluated using an in vivo imaging system. Ole-siRNA had a significant antitumor effect compared with nonmodified siRNA. In addition, mice with metastatic liver Sui67Luc tumors treated with Ole-siRNA showed increased survival. These results suggest that Ole-siRNAs are useful novel RNAi molecules for treating pancreatic cancer and liver metastasis.
Insights
Oleoyl-siRNA (Ole-siRNA) enhances RNA interference (RNAi) for pancreatic cancer liver metastasis. This novel conjugate shows improved in vitro and in vivo antitumor effects and increased survival in mouse models.
Area of Science:
- Molecular Biology
- Oncology
- Drug Delivery
Background:
- Pancreatic cancer frequently metastasizes to the liver, necessitating effective therapeutic strategies.
- RNA interference (RNAi) offers a promising approach for gene silencing in cancer therapy.
- Targeting key genes like β-catenin is crucial for inhibiting tumor growth and metastasis.
Purpose of the Study:
- To develop and evaluate an oleoyl-siRNA (Ole-siRNA) conjugate for enhanced RNAi.
- To assess the efficacy of Ole-siRNA in a mouse model of pancreatic cancer with liver metastasis.
- To investigate the biodistribution, antitumor effects, and survival outcomes of Ole-siRNA treatment.
Main Methods:
- Development of an oleoyl-siRNA conjugate targeting the β-catenin gene.
- Establishment of a mouse model by implanting human pancreatic cancer cells (Sui67Luc) into the portal vein.
- In vitro and in vivo evaluation of Ole-siRNA efficacy, including biodistribution, antitumor activity, and survival analysis using systemic administration with Invivofectamine 3.0 (IVF).
Main Results:
- Ole-siRNA demonstrated a stronger in vitro RNAi effect against β-catenin compared to unmodified siRNA.
- Systemic administration of Ole-siRNA/IVF complex showed accumulation in the liver.
- Ole-siRNA significantly reduced tumor burden and increased survival rates in the mouse model compared to non-modified siRNA.
Conclusions:
- Ole-siRNA is a potent RNAi molecule with enhanced therapeutic potential.
- Ole-siRNA demonstrates significant antitumor effects and improves survival in pancreatic cancer liver metastasis.
- Ole-siRNAs represent a promising novel therapeutic strategy for treating pancreatic cancer with liver metastasis.
